The continuous progression of cancerous severity due to the interaction of physical (ultraviolet radiation), chemical (smoking, mycotoxins, and heavy metals), and biological (microbial populations) carcinogens inspired scientists to develop a correlation between active therapeutic agents and cancer proliferation. This review highlights the molecular mechanism by which lycopene imparts its anticancerous role, focusing on clinical and animal trials to validate its effectiveness. The antioxidant profile of lycopene promotes anticancerous properties that reduce cancer prevalence by activating cell signaling pathways and gene expression (involved in cancer cell proliferation). Lycopene's anti-inflammatory properties suppresses the tumor growth and development-promoting pathways, such as the PI3K/Akt/mTOR pathway. The anticancer property of lycopene is also evidenced by its inhibitory potential of the Wnt/β-catenin signaling pathway that is involved in cancer cell modulation and propagation. Lycopene also suppresses and neutralizes oxidative stress and reactive oxygen species (ROS)-induced DNA damage, preventing gene mutation. Inflammation-induced cell death is mitigated by lycopene's anti-inflammatory potential that lowers the expression of interleukin 6 (IL-6) and tumor necrosis factor-alpha (TNF-α). Several clinical and randomized control trials have revealed the effect of lycopene supplementation in the management of cancer, including breast cancer, pancreatic cancer, prostate cancer, colon cancer, ovarian cancer, skin cancer, oral cancer, liver cancer, gastric cancer, and kidney cancer, by lessening prostate-specific antigen (PSA) levels. These studies also accentuate certain limitations that need further trials to evaluate the long-term consequences of lycopene supplementations and their specific effective dose.
Punicalagin, being a bioactive polyphenol, has gained significant interest owing to its potential anticancer effects. Researchers are studying punicalagin to determine its ability to inhibit cancer cell proliferation. This paper focuses on highlighting the therapeutic potential of punicalagin against tumors and cancers. Punicalagin inhibits tumor growth within the body through various cellular pathway interactions. This compound effectively eliminates tumor cells from the liver, stomach, prostate, and lungs. Different animal model studies have demonstrated the potential of punicalagin in blocking the MAPK/ERK and PI3K/AKT/mTOR signaling pathways, fighting against cancer. Through the inhibition of cell division, punicalagin may be capable of eradicating breast cancer cells. Punicalagin strongly inhibits the activities of vascular endothelial growth factor (VEGF), matrix metalloproteinase-9 (MMP-9), and uPA. Punicalagin effectively inhibits the androgen receptor (AR), a protein essential for the development and metastasis of prostate cancer. Lung cancer cells can be eliminated by initiating the caspase cascade and inhibiting protein synthesis, which is facilitated by punicalagin. In numerous animal models, punicalagin significantly reduces metastasis. Cyclokinase B1 and cyclin-dependent kinase 2 promote colon cancer; when colon cancer cells reach the G2/M phase, punicalagin induces apoptosis by inhibiting the action of these proteins. Punicalagin inhibits tumor development and cancer propagation by inhibiting blood vessel proliferation. There is still a need for further clinical trials and studies to fully reveal punicalagin's potential as well as its safety; despite the fact that it may decrease the threat of increasing tumors and provide an alternative treatment for many cancers.
Georgi. It has been recognized as an active phytochemical with specific therapeutic potential and significant pharmacological effects, especially in cancer research. Nevertheless, increasing preclinical data both in vitro and in vivo demonstrate its effectiveness against a broad spectrum of cancers, including breast, ovarian, lung, gastric, colorectal, prostate, renal, glioblastoma, and hematological types. Wogonin exerts its anticancer effects through a complex mechanism that involves the induction of programmed cell death (apoptosis), autophagic modulation, and cell cycle arrest. It also suppresses angiogenesis of tumors, epithelial-mesenchymal transition (EMT), invasion, metastasis, and multidrug resistance effects. The effects are supported by the compound's ability to regulate a variety of oncogenic and tumor-suppressive signaling pathways, particularly PI3K/Akt, STAT3, NF-kB, MAPK, AMPK, and Wnt/beta-catenin. It modulates apoptosis-related proteins (Bax, Bcl-2, PARP, caspases) and transcription factors. Wogonin has been shown to enhance the antitumor effects of established chemotherapeutic agents, and it works synergistically with these drugs in multiple cancer models, with the added benefits of reduced systemic toxicity. Nevertheless, it has poor oral bioavailability and water solubility, which limits its clinical application. Recent advances in nanocarriers and liposomal delivery systems show promise in overcoming pharmacokinetic challenges. This review consolidates available pharmacological, mechanistic, and pharmacokinetic evidence of wogonin, highlights its potential in combination therapies, and identifies research gaps and formulation strategies necessary for advancing this candidate towards clinical development as a novel anticancer agent.
Journal of Family and Community Medicine · مجلد 32 (1) · 1-15
Prostate cancer (PCa) is a significant health issue characterized by the uncontrolled growth of cells in the prostate gland primarily affecting men 50 years old or older. The aim of this research was to assess the level of knowledge and attitudes of men in the Middle East towards PCa. A comprehensive search strategy in major databases from the date of first publication on this topic to April 2024 was conducted of cross-sectional studies assessing the knowledge and attitudes of adult men in the Middle East toward PCa. Data on the study's methodology, participant characteristics, and outcomes related to the knowledge of PCa and attitudes towards PCa were extracted and analyzed using the comprehensive meta-analysis software. The Newcastle-Ottawa Scale was used for quality assessment. The meta-analysis of 26 studies revealed significant heterogeneity among studies, with an overall rate of previous education on PCa at 76.3% (95% confidence interval [CI]: 61.2%- 86.8%), but a much lower rate of education on PCa screening at 20.5% (95% CI: 7.2%-46.2%). Knowledge of PCa, its screening tools, symptoms, risk factors, and treatments, as well as attitudes towards PCa screening, varied widely, with knowledge rates of 50.5% for PCa, 32.3% for screening tools, 45.5% for symptoms, 49.4% for risk factors, and 58.4% for treatments. The rate of favorable attitude towards PCa screening was reported at 50.0% (95% CI: 36.7%-63.3%). The Middle East has some understanding of PCa but there is little knowledge of screening techniques, symptoms, risk factors, and treatments. To improve early detection and patient outcomes, comprehensive education and culturally sensitive communication strategies are necessary.
prostate cancerprostate cancer screeninghealth knowledgeattitudes toward screening
BACKGROUND: Benign prostatic hyperplasia (BPH) is the most common urological disorder in older males, often treated with prostate artery embolization (PAE) to alleviate lower urinary tract symptoms. While traditional embolic materials like microspheres are common, issues such as symptom recurrence and non-target embolization remain. This systematic review evaluates the safety and effectiveness of n-butyl cyanoacrylate (NBCA) glue as an alternative embolic agent for PAE. MATERIALS AND METHODS: A thorough search was performed across databases including PubMed, ScienceDirect, Cochrane, Google Scholar, Scopus, and MEDLINE. Studies were included if they assessed NBCA glue for PAE in BPH patients. Exclusions were made for reviews, non-English articles, conference abstracts, and studies not using glue or ethiodized oil mixtures. The Methodological Index for Non-Randomized Studies criteria was used to assess bias risk, and due to varied outcome measures, a narrative synthesis was conducted. RESULTS: Six studies involving 667 patients met the inclusion criteria. The age in mean ± SD across studies ranged from 67.5 ± 7.8 to 72.6 ± 10.5 with most patients presenting with moderate to severe BPH unresponsive to medication. NBCA glue-based procedures showed high technical success rates and shorter procedure times. International Prostate Symptom Score improvement was reported in 83-94% of patients across all studies with associated quality of life significantly enhanced in up to 94% of patients as well. Prostate volume reduction ranged from 11% to 40.5%, depending on follow-up duration. PSA levels and medication use decreased, and erectile function was mostly preserved, though results varied. Minor complications like groin hematomas and post-embolization syndrome occurred in 4-22% of patients, with no major adverse events reported. CONCLUSION: This review assesses NBCA-based glue as a potential embolic agent in PAE for BPH. The evidence suggests promising short-term outcomes with a favorable safety profile, though findings remain preliminary due to small sample sizes and short follow-up. Larger multicenter randomized trials are therefore needed to validate these results and guide clinical practice.
Abstract Moringa oleifera, a widely recognized plant more commonly known as moringa, has obtained significant research interest in recent years due to its prospective physiological advantages, including its claimed ability to counteract carcinogenesis. The moringa plant has been found to possess bioactive components that exhibit promising anticancer activities against different human cancers, such as breast cancer, prostate cancer, pancreatic cancer, etc. The cytotoxic properties of moringa seed extracts on cancerous cells have also been provided in this paper along with other notable health benefits. The extracts derived from moringa seeds inhibit cancer proliferation and promote cancer cell apoptosis through multiple signaling pathways. They also stimulated intracellular reactive oxygen species (ROS) production and subsequently induced caspase‐3 activity. The impact of moringin and avenanthramide 2f on the stimulation of caspases 2, 4, 8, and 9 results in reduction in the proliferation of cancer cells. The results reported by research studies hold significant implications for identifying and targeting specific molecular entities that could serve as potential therapeutic targets in search of effective cancer treatments. Furthermore, the flavonoids in moringa seed can remove mitochondrial reactive oxygen species, protecting beta cells and bringing hyperglycemia under control. M. oleifera seed oil can reduce the risk of cardiovascular diseases via reduced malondialdehyde (MDA) formation and modulation of cardiac superoxide dismutase (SOD) and glutathione peroxidase (GPx) activity. This article provides a comprehensive summary of the noteworthy discoveries derived from a rigorous investigation that explored into the impact of moringa seeds on the prevention/reduction of various cancers and other complex diseases.
Prostate cancer is one of the most life-threatening disorders that occur in males. It has now become the third most common disease all over the world, and emerging cases and spiking mortality rates are becoming more challenging day by day. Several approaches have been used to treat prostate cancer, including surgery, radiation therapy, chemotherapy, etc. These are painful and invasive ways of treatment. Primarily, chemotherapy has been associated with numerous drawbacks restricting its further application. The majority of prostate cancers have the potential to become castration-resistant. Prostate cancer cells exhibit resistance to chemotherapy, resistance to radiation, ADT (androgen-deprivation therapy) resistance, and immune stiffness as a result of activating tumor-promoting signaling pathways and developing resistance to various treatment modalities. Nanomedicines such as liposomes, nanoparticles, branched dendrimers, carbon nanotubes, and quantum dots are promising disease management techniques in this context. Nanomedicines can target the drugs to the target site and enhance the drug's action for a prolonged period. They may also increase the solubility and bioavailability of poorly soluble drugs. This review summarizes the current data on nanomedicines for the prevention and treatment of prostate cancer. Thus, nanomedicine is pioneering in disease management.
Mangiferin is a bioactive substance present in high concentration in mangoes and also in some other fruits. Owing to its potential as a chemopreventive and chemotherapeutic agent against several types of cancer, this unique, significant, and well-researched polyphenol has received a lot of attention recently. It possesses the ability to treat cancers, including rectal cancer, prostate cancer, ovarian cancer, leukemia, gastric cancer, liver cancer, chronic pancreatitis, and lung cancer. It can control/regulate multiple key signaling pathways, such as signal transducer and activator of transcription 3 (STAT3), second mitochondria-derived activator of caspases/direct inhibitor of apoptosis (IAP)-binding protein with low propidium iodide (pl) (Smac/DIABLO) nuclear factor kappa B (NF-κB), phosphatidylinositol 3 kinase/protein 3 kinase (PI3K/Akt), transforming growth factor beta/suppressor of mothers against decapentaplegic (TGF-β/SMAD), c-jun N-terminal kinase/p38 mitogen-activated protein kinase (JNK/p38-MAPK), and phosphor-I kappa B kinase (p-IκB), which are crucial to the development of cancers. By triggering apoptotic signals and halting the advancement of the cell cycle, it can also prevent some cancer cell types from proliferating and developing. It has been revealed that mangiferin targets a variety of adhesion molecules, cytokines, pro-inflammatory transcription factors, kinases, chemokines, growth factors, and cell-cycle proteins. By means of preventing the onset, advancement, and metastasis of cancer, these targets may mediate the chemopreventive and therapeutic effects of mangiferin. Mangiferin has confirmed potential benefits in lung, cervical, breast, brain, and prostate cancers as well as leukemia whether administered alone or in combination with recognized anticancer compounds. More clinical trials and research investigations are required to completely unleash the potential of mangiferin, which may lower the risk of cancer onset and act as a preventive and therapeutic alternative for a number of cancers.